CD8A and neoplasm: This combination led to a 3–fourfold increase in CD3 + and CD8 + T-cell infiltration compared to CHOP treatment alone, suggesting that CA inhibitors like acetazolamide can enhance immune responses and support tumor-associated immunotherapies [294].